Efficacy of idebenone combined with citicoline sodium in the treatment of cognitive dysfunction after cerebral infarction
10.3760/cma.j.cn341190-20240526-00640
- VernacularTitle:艾地苯醌联合胞磷胆碱钠治疗脑梗死后认知功能障碍的疗效分析
- Author:
Aning ZHANG
1
;
Ning MIN
Author Information
1. 铜川市人民医院神经内科，铜川 727100
- Publication Type:Journal Article
- Keywords:
Brain infarction;
Hemodynamics;
Cognitive dysfunction;
Acetylcholine;
Brain-derived neurotrophic factor
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(8):1127-1131
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of idebenone combined with citicoline sodium in the treatment of cognitive dysfunction after cerebral infarction.Methods:This prospective study included 150 patients with cognitive dysfunction after cerebral infarction who visited the Department of Neurology at People's Hospital of Tongchuan from October 2020 to October 2023. The patients were randomly divided into two groups: 75 patients in the control group received treatment with citicoline sodium, while the other 75 patients in the treatment group were treated with a combination of idebenone and citicoline sodium. The treatment continued for 2 weeks. Cognitive function was compared between the two groups before and after treatment. Clinical efficacy was compared between the two groups after treatment. Hemodynamic parameters of the middle cerebral artery, serum levels of neuromodulatory substances, and adverse reactions were compared between the two groups.Results:After treatment, the scores of the Mini-Mental State Examination and the Montreal Cognitive Assessment in the treatment group were significantly higher than those in the control group [(26.38 ± 2.76) vs. (23.64 ± 2.41), (25.94 ± 2.60) vs. (22.81 ± 2.31), t = -6.48, -5.97, both P < 0.05]. The total response rate in the treatment group was significantly higher than that in the control group ( χ2 = 6.32, P < 0.05). After treatment, the resistance index and pulsatility index in the treatment group were significantly lower than those in the control group, while the average blood flow velocity was significantly higher in the treatment group compared with the control group. All differences were statistically significant ( t = 13.96, 15.03, -3.96, all P < 0.05). After treatment, serum levels of acetylcholine and brain-derived neurotrophic factor in the treatment group were significantly higher than those in the control group ( t = -9.84, -12.53, both P < 0.05). There was no significant difference in total incidence of adverse reactions, such as gastrointestinal discomfort and central nervous system reactions, between the treatment and control groups [12.00% (9/75) vs. 9.33% (7/75), χ2 = 0.28, P > 0.05]. Conclusions:The combination of idebenone and citicoline sodium for treating cognitive dysfunction after cerebral infarction can promote the recovery of cognitive function in patients. The mechanism behind this improvement is associated with the restoration of cerebral blood flow and the upregulation of neuromodulatory substance levels. The combined use of these two drugs is safe.
